alternatives to Zelnorm now that it's being pulled from the market for possible cardiovascular problems

May 2007

Patients are scrambling for alternatives to Zelnorm now that it's being pulled from the market for possible cardiovascular problems.

Zelnorm (tegaserod) is associated with a 0.1% increase in cardiovascular events...compared to a 0.01% placebo rate.

Zelnorm's benefits are modest.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote